Pacira's (PCRX) Exparel Meets Key Goals In C-Section Study
Zacks Investment Research | Jan 07, 2020 11:16PM ET
Pacira BioSciences, Inc. (NASDAQ:PCRX) announced that the phase IV CHOICE study on its lead drug Exparel in patients undergoing Cesarean section (C-section) achieved its primary endpoint with a statistically significant reduction in total postsurgical opioid consumption through 72 hours (P≤0.001).
The study also achieved the key secondary endpoint with Exparel demonstrating statistical significance for reduction in the incidence and severity of itching through 72 hours following surgery.
Per the company, 169 patients undergoing elective C-section in the study were randomized to receive either 150 mcg morphine spinal anesthesia + standard of care postoperative pain regimen, 50 mcg morphine spinal anesthesia plus Exparel transversus abdominis plane (TAP) field block or an opioid-free spinal anesthesia + Exparel TAP block.
Notably, in the EXPAREL arms, patients were administered with a protocol-defined postoperative pain management regimen comprising ketorolac, acetaminophen and ibuprofen. Importantly, the Exparel TAP block demonstrated superiority over morphine spinal-based standard of care.
Shares of Pacira have rallied 11.3% in the past year compared with the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.